301126.Sz

The company's capital structure is characterized by a high debt-to-equity ratio of 2.47, indicating a significant reliance on debt financing. The liquidity position is assessed as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The operating cash flow is negative at -149,119,030 CNY, and capital expenditures are also negative at -104,633,310 CNY, indicating ongoing investment in the business.

Profitability and returns are not explicitly detailed in the provided data, but the company's operating cash flow and capital expenditures suggest ongoing operational and investment activities. The debt-to-equity ratio of 2.47 indicates a leveraged capital structure, which may impact the company's financial flexibility and cost of capital.

The company's segments and geographic exposure are not detailed in the provided data. However, the business is primarily focused on drug retailing, which may involve a mix of domestic and international operations depending on the company's market presence.

The company's growth trajectory is not explicitly detailed in the provided data. However, the ongoing capital expenditures suggest a commitment to expansion or modernization. The revenue for the latest period is 5,144,237,120 CNY, indicating a substantial revenue base.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash after subtracting total debt, which may impact the company's ability to meet short-term obligations. The dilution potential is assessed as low, suggesting minimal immediate threat to shareholder equity.

Recent events and filings are not detailed in the provided data. However, the company's financial snapshot and risk assessment suggest ongoing operational and financial activities that may be reflected in future filings and disclosures.